The structure of TMEM16A in a blocker-bound, partially open state presented here may thus lead to the rational design of specific small molecules for its therapeutic targeting in conditions such as hypertension, asthma, and cystic fibrosis. Here, ANO1 is linked to cystic fibrosis.